Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 2522

1.

Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.

He K, Wang X, Guan X, Yu Q, Ma Q, Liu Z, Yu Z.

Anticancer Res. 2017 Oct;37(10):5647-5653.

PMID:
28982882
2.

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up.

Kolek V, Grygárková I, Koubková L, Skřičková J, Švecová J, Sixtová D, Bartoš J, Tichopád A.

PLoS One. 2017 Jul 21;12(7):e0181803. doi: 10.1371/journal.pone.0181803. eCollection 2017.

3.

Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.

Yamamura J, Masuda N, Yamamoto D, Tsuyuki S, Yamaguchi M, Tanaka S, Tsurutani J, Tokunaga S, Yoshidome K, Mizutani M, Aono T, Ooe A, Tanino H, Matsunami N, Yasojima H, Nakayama T, Nishida Y.

Chemotherapy. 2017;62(5):307-313. doi: 10.1159/000475879. Epub 2017 Jun 13.

PMID:
28605730
4.

A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).

Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V.

Br J Cancer. 2017 Jun 27;117(1):33-40. doi: 10.1038/bjc.2017.145. Epub 2017 Jun 6.

PMID:
28588322
5.

Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.

Mencoboni M, Filiberti RA, Taveggia P, Del Corso L, Del Conte A, Covesnon MG, Puccetti C, Donati S, Auriati L, Amoroso D, Camerini A.

Anticancer Res. 2017 Jun;37(6):3189-3194.

PMID:
28551663
6.

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.

Kogo M, Sunaga T, Nakamura S, Akita T, Kurihara T, Shikama Y, Nakajima H, Tobe T, Yoneyama K, Kiuchi Y.

Chemotherapy. 2017;62(4):239-245. doi: 10.1159/000468508. Epub 2017 May 5.

PMID:
28472787
7.

Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.

Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, Stacchiotti S, Casali PG, Gronchi A.

Cancer J. 2017 Mar/Apr;23(2):86-91. doi: 10.1097/PPO.0000000000000254.

PMID:
28410293
8.

Validated UHPLC-MS/MS assay for quantitative determination of etoposide, gemcitabine, vinorelbine and their metabolites in patients with lung cancer.

Gong X, Yang L, Zhang F, Liang Y, Gao S, Liu K, Chen W.

Biomed Chromatogr. 2017 Nov;31(11). doi: 10.1002/bmc.3989. Epub 2017 Jun 15.

PMID:
28409868
9.

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS.

Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.

10.

A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801).

Kawaguchi K, Yokoi K, Niwa H, Ohde Y, Mori S, Okumura S, Shiono S, Ito H, Yano M, Shigemitsu K, Hiramatsu Y, Okami J, Saka H; Central Japan Lung Study Group.

Lung Cancer. 2017 Feb;104:79-84. doi: 10.1016/j.lungcan.2016.12.011. Epub 2016 Dec 21.

PMID:
28213006
11.

Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.

Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, Lai A, Goldhirsch A, Colleoni M.

Cancer Lett. 2017 Aug 1;400:276-281. doi: 10.1016/j.canlet.2017.01.027. Epub 2017 Jan 26.

PMID:
28131905
12.

Baicalein attenuates vinorelbine-induced vascular endothelial cell injury and chemotherapeutic phlebitis in rabbits.

Ge GF, Shi WW, Yu CH, Jin XY, Zhang HH, Zhang WY, Wang LC, Yu B.

Toxicol Appl Pharmacol. 2017 Mar 1;318:23-32. doi: 10.1016/j.taap.2017.01.013. Epub 2017 Jan 23.

PMID:
28126410
13.

Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.

Feng F, Wang B, Sun X, Zhu Y, Tang H, Nan G, Wang L, Wu B, Huhe M, Liu S, Diao T, Hou R, Zhang Y, Zhang Z.

Cancer Biol Ther. 2017 Jan 2;18(1):51-62. doi: 10.1080/15384047.2016.1276126.

15.

Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression.

Sowa T, Menju T, Chen-Yoshikawa TF, Takahashi K, Nishikawa S, Nakanishi T, Shikuma K, Motoyama H, Hijiya K, Aoyama A, Sato T, Sonobe M, Harada H, Date H.

Cancer Med. 2017 Jan;6(1):288-297. doi: 10.1002/cam4.991. Epub 2016 Dec 28.

16.

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.

Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, Nanni O, Miller WH Jr, Panasci LC.

PLoS One. 2016 Dec 19;11(12):e0167906. doi: 10.1371/journal.pone.0167906. eCollection 2016.

17.
18.

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, Gibson N, Uttenreuther-Fischer M, Herrero J, Swanton C.

PLoS Med. 2016 Dec 6;13(12):e1002136. doi: 10.1371/journal.pmed.1002136. eCollection 2016 Dec.

19.

Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer.

Sjøblom B, Benth JŠ, Grønberg BH, Baracos VE, Sawyer MB, Fløtten Ø, Hjermstad MJ, Aass N, Jordhøy M.

Clin Lung Cancer. 2017 Mar;18(2):e129-e136. doi: 10.1016/j.cllc.2016.09.008. Epub 2016 Oct 5.

PMID:
27825639
20.

Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

Hendriks LE, Brouns AJ, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JS, De Ruysscher DK, Van den Heuvel MM, Dingemans AC.

Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008. Epub 2016 Sep 9.

Supplemental Content

Support Center